In Japan, the treatment landscape for inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is mature and encompassing many conventional therapies as well as novel therapies including biologics and a small molecule. With the increasing competition from biosimilars and the late-stage pipeline drugs, key players with novel therapies are offering comprehensive […]